162 related articles for article (PubMed ID: 15755586)
41. New gene-based approaches for an AIDS vaccine.
Puaux AL; Michel ML
Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):357-72. PubMed ID: 12818622
[TBL] [Abstract][Full Text] [Related]
42. Utility of SHIV for testing HIV-1 vaccine candidates in macaques.
Lu Y; Salvato MS; Pauza CD; Li J; Sodroski J; Manson K; Wyand M; Letvin N; Jenkins S; Touzjian N; Chutkowski C; Kushner N; LeFaile M; Payne LG; Roberts B
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):99-106. PubMed ID: 8680896
[TBL] [Abstract][Full Text] [Related]
43. Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory.
Demberg T; Ettinger AC; Aladi S; McKinnon K; Kuddo T; Venzon D; Patterson LJ; Phillips TM; Robert-Guroff M
Vaccine; 2011 Aug; 29(35):6017-28. PubMed ID: 21708207
[TBL] [Abstract][Full Text] [Related]
44. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies.
Jaspan HB; Robinson JE; Amedee AM; Van Dyke RB; Garry RF
J Clin Virol; 2004 Nov; 31(3):190-7. PubMed ID: 15465411
[TBL] [Abstract][Full Text] [Related]
45. Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques.
Lu P; Guerin DJ; Lin S; Chaudhury S; Ackerman ME; Bolton DL; Wallqvist A
Front Immunol; 2021; 12():625030. PubMed ID: 34046030
[TBL] [Abstract][Full Text] [Related]
46. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides.
Belliard G; Hurtrel B; Moreau E; Lafont BA; Monceaux V; Roques B; Desgranges C; Aubertin AM; Le Grand R; Muller S
Vaccine; 2005 Feb; 23(11):1399-407. PubMed ID: 15661389
[TBL] [Abstract][Full Text] [Related]
47. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.
Lederman MM; Veazey RS; Offord R; Mosier DE; Dufour J; Mefford M; Piatak M; Lifson JD; Salkowitz JR; Rodriguez B; Blauvelt A; Hartley O
Science; 2004 Oct; 306(5695):485-7. PubMed ID: 15486300
[TBL] [Abstract][Full Text] [Related]
48. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?
O'Connor D; Allen T; Watkins DI
Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292
[TBL] [Abstract][Full Text] [Related]
49. Vaccines. Monkey puzzles.
Cohen J
Science; 2002 Jun; 296(5577):2325-6. PubMed ID: 12089425
[No Abstract] [Full Text] [Related]
50. Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration.
Kumar A; Liu Z; Sheffer D; Smith M; Singh DK; Buch S; Narayan O
Virology; 2008 Feb; 371(2):238-45. PubMed ID: 17988702
[TBL] [Abstract][Full Text] [Related]
51. Paradigm change in immune correlation: cellular or humoral?
Matsuo K; Yamamoto N
Expert Rev Vaccines; 2010 Sep; 9(9):985-7. PubMed ID: 20822339
[No Abstract] [Full Text] [Related]
52. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.
Rasmussen RA; Siddappa NB; Lakhashe SK; Watkins J; Villinger F; Ibegbu C; Florese RH; Robert-Guroff M; Montefiori DC; Forthal DN; O'Connor D; Ruprecht RM;
AIDS; 2012 Jan; 26(2):149-55. PubMed ID: 21941166
[TBL] [Abstract][Full Text] [Related]
53. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
Warren JT; Dolatshahi M
J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
[No Abstract] [Full Text] [Related]
54. AIDS 1995. Vaccines and immunology: overview.
Montelaro RC; Wigzell H
AIDS; 1995; 9 Suppl A():S111-2. PubMed ID: 8819577
[No Abstract] [Full Text] [Related]
55. [HIV vaccine].
Matano T
Nihon Rinsho; 2005 May; 63 Suppl 5():659-65. PubMed ID: 15954426
[No Abstract] [Full Text] [Related]
56. Prospects for vaccine protection against HIV-1 infection and AIDS.
Letvin NL; Barouch DH; Montefiori DC
Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
[TBL] [Abstract][Full Text] [Related]
57. Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine.
Nehete PN; Gambhira R; Nehete BP; Sastry KJ
J Med Primatol; 2003 Apr; 32(2):67-73. PubMed ID: 12823628
[TBL] [Abstract][Full Text] [Related]
58. Primate models of AIDS vaccine development.
Lamb-Wharton RJ; Joag SV; Stephens EB; Narayan O
AIDS; 1997; 11 Suppl A():S121-6. PubMed ID: 9451975
[No Abstract] [Full Text] [Related]
59. Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model.
Barratt-Boyes SM; Brown KN; Melhem N; Soloff AC; Gleason SM
Immunol Res; 2006; 36(1-3):265-74. PubMed ID: 17337787
[TBL] [Abstract][Full Text] [Related]
60. HIV/AIDS in China. Vaccine development with a distinctly Chinese flavor.
Cohen J
Science; 2004 Jun; 304(5676):1437. PubMed ID: 15178780
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
